<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/19/oragenics-nyseamericanogen-stock-price-down-7-3.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-19T22:18:41+00:00"/>
    <meta property="og:title" content="Oragenics (NYSEAMERICAN:OGEN) Stock Price Down 7.3%"/>
    <meta property="og:description" content="Oragenics Inc (NYSEAMERICAN:OGEN)’s stock price traded down 7.3% during trading on Tuesday . The stock traded as low as $0.51 and last traded at $0.51, 922,900 shares changed hands during mid-day trading. A decline of 15% from the average session volume of 1,091,924 shares. The stock had previously closed at $0.55. Separately, HC Wainwright restated […]"/>
  </head>
  <body>
    <article>
      <h1>Oragenics (NYSEAMERICAN:OGEN) Stock Price Down 7.3%</h1>
      <address><time datetime="2019-11-19T22:18:41+00:00">19 Nov 2019, 22:18</time> by <a rel="author" href="https://www.thecerbatgem.com/author/teresa" target="_blank">Teresa Graham</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Oragenics Inc (NYSEAMERICAN:OGEN)’s stock price traded down 7.3% during trading on Tuesday . The stock traded as low as $0.51 and last traded at $0.51, 922,900 shares changed hands during mid-day trading. A decline of 15% from the average session volume of 1,091,924 shares. The stock had previously closed at $0.55.</p>
      <p>Separately, HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Oragenics in a research note on Thursday, September 26th.</p>
      <p><b>Oragenics Company Profile</b> (<a href="https://www.marketbeat.com/stocks/NYSEAMERICAN/OGEN/">NYSEAMERICAN:OGEN</a>)</p>
      <p>Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-is-the-definition-of-arbitrage/">Understanding the two types of arbitrage</a></p>
    </article>
  </body>
</html>